Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Louisville Hematology Highlights

R. Gale

ASCO® 2024 Summary: "Lymphoma Highlights"

2024 ASCO® Annual Meeting Insights Hub

B. D. Cheson

Multiple Myeloma: A Journey From Pharaoh's Times to 2024

Houston Methodist

S. Ganguly

ASH 2024 Insights: POLARIX 5yr Update - Pola-R-CHP vs. R-CHOP in 1L …

2024 ASH Annual Meeting Insights Hub

G. Salles

2024 Updates on Management of DLBCL

Louisville Hematology Highlights

J. Leonard

Has the 1L SoC Truly Changed in Advanced Stage DLBCL?

SOHO Brazil 2024

A. Zelenetz

Sequencing Cellular Therapy and Bispecific Antibodies in DLBCL

Megan Melody

ASH 2024 Summary: Transplant in Myeloma - Key Factors in Decision-Ma…

2024 ASH Annual Meeting Insights Hub

A. Perrot

Advances in Multiple Myeloma 2024: From Bench to Bedside

Dana-Farber Cancer Institute

K. Anderson

Treating Patients With DLBCL Who Are Not Eligible for CAR-T Therapy

Remy Dulery

ASH 2024 Insights: Outcomes With Bispecific Antibodies Post-CAR T-Ce…

2024 ASH Annual Meeting Insights Hub

M. Melody

Managing R/R LBCL Patients Treated With Pola-R-CHP in 1L and Are CAR…

University of Colorado Cancer Center

M. Kamdar

Lymphoma Hot Topics in 2024: Focus on DLBCL and cHL

Yale Cancer Center

T. Sethi

HSCT in 2024: What Every Hematologist Needs to Know

Indy Hematology Review

R. Childs

Managing Newly Diagnosed MM in 2024

Indy Hematology Review

S. Usmani

The Relapsed and Refractory MM Patient: When Immune Approaches Are I…

Joseph Mikhael

Sequencing of Bispecifics With Other Therapies in DLBCL

UChicago Medicine

E. Budde

Tafasitamab + Lenalidomide vs. CIT for Transplant-Ineligible R/R DLB…

Patrizia Mondello

ASH 2024 Insights: Secondary Heme Malignancies in Myeloma Post-CAR-T…

2024 ASH Annual Meeting Insights Hub

J. Waldschmidt

Current Advances in the Treatment of Aggressive B- and T-Cell Lympho…

Indy Hematology Review

S. Smith